Feasibility, single-group psilocybin-assisted psychotherapy pilot (n≈15) delivering one 25 mg oral psilocybin session with preparatory and integration therapy for demoralization in hospice patients.
This feasibility study evaluates a single 25 mg oral psilocybin administration combined with supportive psychotherapy (two preparation sessions and two integration sessions) for demoralization in patients receiving hospice care.
Primary aims are to assess safety and tolerability in a terminally ill population and to gather preliminary data on reductions in psychological and existential distress over a 24-week follow-up.
Approximately 15 participants will be enrolled; key assessments include demoralization scores, safety labs, and monitoring for suicidal ideation and adverse events.
Single-group PATH intervention: single oral psilocybin administration (25 mg) with supportive psychotherapy (2 preparation sessions, 2 integration sessions).
Single 25 mg oral psilocybin dose.
Two preparation sessions and two integration sessions paired with dosing; behavioural therapy component.